India to roll out drug costing just 1 percent of global price to combat sickle cell disease

It is more common in the tribal population of India but occurs in non-tribals too. It causes anemia and pain, reduces growth, and affects many organs like the lungs, heart, kidneys, eyes, bones and brain. India has the largest density of tribal population, globally.It is a genetic disorder causing red blood cells to assume a sickle shape, leading to premature cell death and blood flow obstruction. While rare, this condition remains incurable.Announcing the drug, Akmus Drugs and Pharmaceuticals Limited said they have “achieved a ground-breaking milestone: the development of India’s first room temperature stable oral suspension of Hydroxyurea, tailored specifically for patients battling sickle cell disease, spanning across all age groups.”“This innovative product is thoughtfully accompanied by oral syringes for precise dosage administration.”The pharma company said that in contrast to the current import price of approximately Rs. 77,000 for the global brand of Hydroxyurea solution (which necessitates storage at 2-8 Celsius), Akmus is passionately committed to advancing a noble cause and ensuring accessibility to affordable medication.



Source link